Relapse of multiple myeloma in extramedullary sites after autologous bone marrow transplantation
Authors:
- C. SanfructuosoCSC. Sanfructuoso
- M D CaballeroMCM D Caballero
- R Garcia‐SanzR Garcia‐Sanz
- B VidrialesBVB Vidriales
- L. VazquezLVL. Vazquez
- J.F. SanJSJ.F. San
- 1 March 1996
- journal article
- Published by Wiley in European Journal of Haematology
- Vol. 56 (3) , 181-183
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- High-dose melphalan is not associated with extramedullary relapses in high-risk multiple myeloma.Journal of Clinical Oncology, 1993
- Extramedullary progression of multiple myeloma following GM‐CSF treatment — grounds for caution?European Journal of Haematology, 1992
- High-risk multiple myeloma treated with high-dose melphalan.Journal of Clinical Oncology, 1992
- Immunophenotypic heterogeneity of multiple myeloma: influence on the biology and clinical course of the diseaseBritish Journal of Haematology, 1991
- Granulocyte-macrophage colony-stimulating factor synergizes with interleukin-6 in supporting the proliferation of human myeloma cells [see comments]Blood, 1990
- Plasma cells in multiple myeloma express a natural killer cell- associated antigen: CD56 (NKH-1; Leu-19)Blood, 1990
- Plasmacytoma growth factor activity of murine granulocyte-macrophage colony-stimulating factor.The Journal of Immunology, 1988
- Anaplastic myeloma with massive extramedullar involvement: Report of two casesCancer, 1983
- Aggressive phase of multiple myeloma with pulmonary cell infiltrates1982
- Ploidy and proliferative characteristics in monoclonal gammopathiesBlood, 1982